Beijing SL Pharmaceutical Co., Ltd.
双鹭药业
002038
Shenzhen Stock Exchange
Company Profile
SL PHARM has been focusing on the research and development and production of genetic engineering and related drugs since founded. Its products cover tumor, cardiovascular and cerebrovascular, anti-infective immunity, diabetes, wound repair, and liver and kidney disease therapeutic field. Our current research includes long-acting protein drugs, high-end genetic engineering drugs and vaccines, specialty patented drugs, Me-better antibody drugs and specialty biochemical drugs. The company started early in the research of genetic engineering drugs. The quantity and quality of self-developed biotechnology new drugs are at the domestic leading level, and the key technologies are internationally advanced and domestically leading. The main products include recombinant human granulocyte colony stimulating factor(national key new products, Beijing famous brand product); recombinant human new interleukin-2(rhIL-2, the first alanine mutant IL-2, national key new product),; recombinant human IL-11, (the first listed IL-11 in China, funded by the “863” Fund and the National Enterprise Technology Innovation Fund, Beijing Invention Patent Award), recombinant human basic fibroblast growth factor(national first-class new drug, granted 12-years administrative protection by the state, national first-class new drug), and so on. Meanwhile, SL PHARM actively used genetic engineering technology to transform traditional biochemical drugs and successively launched a number of competitive products, including compound coenzyme (exclusive product), loratadine dispersible tablets, thymopentin and other more than ten products. With the constant drug increase, the product lines in tumors, liver diseases, metabolic diseases and cardiovascular and cerebrovascular products were gradually established. At present, SL PHARM has many potential products, including long-acting protein drugs, high-end vaccines, specialty patented drugs, Me-too, Me-better recombinant drugs and specialty biochemical drugs, and all of these lay a solid foundation for the company’s performance.
Full description
Beijing SL Pharmaceutical Co., Ltd. founded in 1994, is the first listed company in Beijing to enter the SMEs board and a state-certified enterprise technology center. Since its establishment, relying on its technological advantage and continuous innovation, we have researched and developed 2 first class new drugs with independent intellectual property rights and 8 second class new drugs, formed product lines in cancer, geriatric diseases and liver diseases therapeutic field. The company has won 1 National Science and Technology Progress Second Award, 1 Army Science and Technology Progress First Award, and 9 Beijing Science and Technology Progress Awards, and has applied and won National “863” Program Fund support as an independent enterprise. Several projects have been funded by the National Technology Innovation Fund. SL PHARM is the industrialization base of four national “863” programs, and its marketing network covers the first and second tier cities in China. SL PHARM is a key high-tech enterprise of the National Torch Program, a national technology innovation demonstration enterprise, a Zhongguancun bio-industry innovation base, a demonstration enterprise of Beijing industrial enterprise intellectual property use, a Beijing International Science and Technology Cooperation Base, a Beijing High-tech Achievements Transformation Demonstration Enterprise, a Haidian Enterprise Post-doctoral Workstation, and a Beijing “G20” Phase I Project Excellent Enterprise.